Ms Jayne Wilson BSc MSc

Institute of Cancer and Genomic Sciences
Senior Systematic Reviewer

Contact details

Email
j.s.wilson.1@bham.ac.uk
View my research portal
Address
Cancer Research UK Clinical Trials Unit (CRCTU),
Institute of Cancer and Genomic Sciences,
University of Birmingham,
Edgbaston,
Birmingham,
B15 2TT

Jayne has been working in the area of systematic reviews for 23 years. She joined the University of Birmingham in 2001 and has worked in various departments such as public health and cancer trials. She is currently Team Leader for the Cancer Research Clinical Trials Unit (CRCTU) Systematic Reviews Team.

Qualifications

Health Technology Assessment – Decision Making for Health, Agence d’evaluation des technologies et des modes d’intervention en santé  – Distance Learning Course, Quebec. 2004 

MSc Museum Studies, University of Leicester. 1995-96 

BSc Ecology, Kings College London. 1989-92 

Registered General Nurse, Nottingham School of Nursing. 1983-86

Biography

Jayne started working life training to be a Registered General Nurse, at Nottingham School of Nursing. Post qualification she specialised in cardiothoracic intensive care nursing in the regional heart unit for the East Midlands in Leicester. Later she studied at Kings College London, for a BSc in Biology, specializing in Ecology and then at Leicester University for an MSc in Museum Studies specializing in DNA recovery from old biological specimens.

Serendipity in 1997 gave Jayne the opportunity to get involved in medical research, first collecting data from GP practices for a trial investigating guideline formats in angina and asthma (Department of General Practice, Leicester University) and a community study on depression in the elderly (Department of Epidemiology, Leicester University). During this time Jayne gained experience in systematic reviewing which led to a post in 1999 as systematic reviewer on a project investigating Chlamydia trachomatis (Department of Obstetrics and Gynaecology, Aberdeen University).

After her very enjoyable stint in Scotland, Jayne joined Birmingham University in February 2001 to join the West Midlands Health Technology Assessment Collaboration (WMHTAC) based in the Department of Public Health http://www.birmingham.ac.uk/research/activity/mds/projects/HaPS/PHEB/WMHTAC/contact/index.aspx. The first four years were spent working on reviews for customers such as NICE and the Department of Health, before becoming a reviewer and analyst for ARIF, where she undertook rapid literature assessments for customers within West Midlands PCTs.

In December 2010 Jayne became the Team Leader for the CRCTU Systematic Reviews Team within the Institute of Cancer and Genomic Sciences working on reviews to support the trials. Recently, she has been PI on two RfPB NIHR grants, the first reviewing treatments for children with brain tumours, the second conducting a review of reviews on treatments to help patients who have had head and neck cancer treatment who have been left with treatment sequelae. 

Teaching

Previously tutor on the CASPb and a module co-ordinator on the MPH (HTA). Currently Jayne supports undergraduate and postgraduate students wanting to undertake systematic reviews. 

Research

Grants held:

PB-PG-1112-29122 - Systematic reviews of treatments for children’s cancer – central nervous system tumours. Award held 2014 to 2018.

RfPB – NIHR 200577: Systematic review of systematic reviews to assess the effectiveness of interventions to improve long-term sequelae in patients with head and neck cancer.

 

Research interests:

Utilization of systematic reviews to support trial development

Critical appraisal of Systematic Reviews and other study designs

Ongoing trials 

Publications

Majothi S, et al. FLT3 inhibitors in acute myeloid leukaemia: assessment of clinical effectiveness, adverse events and future research systematic review and meta-analysis: Systematic Reviews 285, vol 9, issue 1 2021.

Gurung, P. M. S., A. R. Barnett, J. S. Wilson, J. Hudson, D. G. Ward, E. M. Messing, and R. T. Bryan, Prognostic DNA Methylation Biomarkers in High-risk Non-muscle-invasive Bladder Cancer: A Systematic Review to Identify Loci for Prospective Validation. LID - S2405-4569(19)30032-X [pii] LID - 10.1016/j.euf.2019.02.012 [doi]: Eur Urol Focus, v. 2019, no. 19, p. 10.

Stevens SP, Main C, Bailey S, et al. The utility of routine surveillance screening with magnetic resonance imaging to detect tumor recurrence/progression in children withhigh-grade central nervous system tumors:asystematicreview. Pediatr Blood Cancer.2018; e27509. https://doi.org/10.1002/pbc.27509

S. P. Stevens et al. The utility of routine surveillance screening with magnetic resonance imaging (MRI) to detect tumour recurrence in children with low-grade central nervous system (CNtumours: a systematic review, 2018 J NEUROONCOL.507, 507-522 .

Parrott M, Kelleher M, Rule S, Wilson J. A Systematic Review of Treatments of Relapsed/Refractory Mantle Cell Lymphoma. Clinical Lymphoma, Myeloma, Leukemia 18(1), 13-25. 2018.

J. J. D'Costa et al. A Systematic Review of the Diagnostic and Prognostic Value of Urinary Protein Biomarkers in Urothelial Bladder Cancer, 2 BLADDER.CANCER.301, 301-317 (2016).

M. Braun et al. The Stricter the Better? The Relationship between Targeted HbA1c Values and Metabolic Control of Pediatric Type 1 Diabetes Mellitus, 2016 J.DIABETES RES.5490258, 5490258 (2016).

C. Main et al. The impact of routine surveillance screening with magnetic resonance imaging (MRI) to detect tumour recurrence in children with central nervous system (CNS) tumours: protocol for a systematic review and meta-analysis, 5 SYST.REV.143, 143 (2016).

C. Main et al. The effectiveness and safety of proton beam radiation therapy in children with malignant central nervous system (CNS) tumours: protocol for a systematic review, 5 SYST.REV.124, 124 (2016).

C. Main et al. The role of high-dose myeloablative chemotherapy with haematopoietic stem cell transplantation (HSCT) in children with central nervous system (CNS) tumours: protocol for a systematic review and meta-analysis, 4 SYST.REV.168, 168 (2015).

Moroz V, Wilson JS, Kearns P, Wheatley K. Comparison of anticipated and actual control group outcomes in randomised trials in paediatric oncology provides evidence that historically controlled studies are biased in favour of the novel treatment. Trials. 2014 Dec 10;15:481

Loke J, Khan JN, Wilson JS, Craddock C, Wheatley K. Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia. Ann Hematol (online version of this article Ann Hematol. 2015 Mar;94(3):361-73 Ann Hematol (online version of this article (doi:10.1007/s00277-014-2218-6)

Wilson JS, Gains JE, Moroz V, Wheatley K, Gaze MN. A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma. Eur J Cancer 2014 Mar, 50(4):801-15. Epub 2013 Dec 12

Greenheld W, Wilson J, Bayliss S, Hyde C. The clinical and cost-effectiveness of intensive versus standard lipid lowering with statins in the prevention of cardiovascular events amongst patients with acute coronary syndromes: a systematic review. Report number 68, 2008, Department of Public Health and Epidemiology, University of Birmingham. ISBN 070442696X - 9780704426962

Wilson J, Wang D, Meads C. Simple interventions to prevent respiratory and gastrointestinal infection in children in day care and school settings – a systematic review and economic evaluation. Report number 57, 2006. Department of Public Health and Epidemiology, University of Birmingham. ISBN No: 0704426102-9780704426108.

Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Djulbegovic B, Bennett CL, Langensiepen S, Hyde C, Engert A. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. Journal of National Cancer Institute 2006; 17; 98(10):708-14.

Wilson J, Yao GL, Raftery J, Bohlius J, Brunskill S, Sandercock J, Bayliss S, Moss P, Stanworth S, Hyde C. A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technology Assessment 2007; 11 (13): 1-202.

Wilson J, Connock M, Song F, Yao G, Fry-Smith A, Raftery J, Peake D. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation. Health Technology Assessment 2005; 9(25):1-142.

Song FJ, Fry-Smith A, Davenport C, Bayliss S, Adi Y, Wilson JS, Hyde C. Identification and assessment of ongoing trials in health technology assessment reviews. Health Technology Assessment 2004; 8(44); 1-87.

Barton P, Jobanputra P, Wilson J, Bryan S, Burls A, The use of modelling to evaluate new drugs for patients with chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technology Assess 2004; 8(11)

Jobanputra P, Wilson J, Douglas K, Burls A. A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis. Rheumatology (Oxford). 2004 Feb;43(2):206-10.

Wilson J, Fry-Smith A, Goodwin J, Hawker J, Taylor R. A systematic review of the biological and health effects of exposure to cold temperature in healthy and diseased adults including the elderly. Department of Health 2002.

Wilson JS, Honey E, Templeton A, Paavonen J, Mardh PA, Stay-Pedersen B; EU Biomed Concerted Action Group. A systematic review of the prevalence of Chlamydia trachomatis among European women. Human Reprod Update 8(4);385-94 2002. 

View all publications in research portal